Pluri Inc.
PLUR
NASDAQ·Healthcare·Biotechnology·Mkt cap $14.7M
$1.36
▼ -0.73%
P/E
-2.09
Mkt Cap
$14.7M
52-Wk Range
$1.25–$5.17
52-Week Range
$1.25 - $5.17
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 71.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Value
Valuation data unavailable
Momentum
Falling
-42.4% over 3m
Quality
Thin
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PLUR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 23, 2026
Most recent quarter reported revenue of $316.0K. Reported EPS of -$0.65.
Reported EPS · last 4Q
Q1 26
-$0.65
Revenue trend · last 1Q
—
Q1 26
$316.0K
Margins · last 1Q
Profit
-1851.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How PLUR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.